About this trial
Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.
This study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.
Eligibility criteria
Qualifiers
Adult patients
Patients with an implantable electronic heart device (CIEDs)
The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025
Disqualifiers
Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation
Patients with severe valvular heart disease, congenital heart disease, or arrhythmias
Patients with single-chamber pacemakers or poor images
Trial design
Treatments tested in this trial
- Pacemaker implantation
Treatment groups
Sponsors and collaborators
Haiyan Wang
Lead sponsor
Qianfoshan Hospital
Sponsor institution